CBA 2016 Annual Conference
- Morning Keynote speaker Dr. Lawrence Steinman (Professor, Stanford)
- Afternoon Keynote speaker Dr. Michele Cleary (VP and Head, Bristol-Myers Squibb)
- Dr. Betty Chang (VP, Pharmacyclics, an Abbvie Company)
- Dr. Lawrence Gan (President and CEO, Development Center for Biotechnology, Taiwan)
- Dr. Ruhong Jiang (Co-founder and CEO, Applied StemCell, Inc)
- Dr. Jack Li (Associate Professor, University of San Francisco)
- Dr. Cheng Liu (Founder & CEO, Eureka Therapeutics)
- Dr. Henry Lu (VP, WuXi AppTec)
- Dr. Yang Pan (Director of Biomarker Sciences, Gilead)
- Dr. Juha Punnonen (Executive Director, Merck)
- Dr. Stanley Qi (Assistant Professor, Stanford)
Registration:
Active CBA members:
$20 online registration from Sept 19th to Oct 4th. Lunch included. Online registration closed.
$30 onsite. Lunch not guaranteed.
Non-Members
$45 online registration from Sept 19th to Oct 4th. Lunch included. Online registration closed.
$55 onsite. Lunch not guaranteed.
Conference Video Highligts
2016 CBA Annual Conference Agenda
8:30 – 9:00 am | Registration, Networking & Exhibitions |
9:00 – 9:05 am | Welcome and Opening Remarks Dr. Kai Zheng, 2016 CBA president |
9:05 – 9:10 am | Conference Introduction Dr. Mark Chen, 2016 CBA Conference Chair |
Session I: Therapeutic discovery Moderator: Dr. Huifang Li |
|
9:10 – 9:50 am | Morning keynote presentation: Molecular guardians in inflammatory disease Dr. Lawrence Steinman, Professor, Stanford University |
9:50 – 10:20 am | The landscape and capabilities of new drug discovery and development in Taiwan Dr. Lawrence Gan, President and CEO, Development Center for Biotechnology |
10:20 – 10:30 pm | Networking & Exhibitions |
10:30 – 11:00 am | Genomics and translational science for drug discovery and clinical development Dr. Henry Lu, Vice President, WuXi AppTec |
11:00 – 11:30 am | The development of ibrutinib, a first-in-class small molecule BTK inhibitor Dr. Betty Chang, Vice President, Pharmacyclics |
11:30 – 11:45 am 11:45 – 12:00 pm |
Sponsor presentation by Merck, Simcere, and Gilead Networking & Exhibitions |
Lunch Session Moderator: Dr. Patrick Yang |
|
12:00 – 12:35 pm | History of anti-ulcer drugs Dr. Jack Li, Associate Professor, University of San Francisco |
12:35 – 12:45 pm | Ho Family Scholarship Award Mr. Caesar Ho |
12:45 – 1:00 pm | Networking & Exhibitions |
Session II: Translational Science Moderator: Dr. Shian-Jiun Shih |
|
1:00 – 1:40 pm | Afternoon keynote presentation: Enabling drug development through translation Research Dr. Michele Cleary, Vice President and Head, Bristol-Myers Squibb |
1:40 – 2:10 pm | Optimize biomarker strategy for clinical drug development Dr. Yang Pan, Director of Biomarker Sciences, Gilead |
2:10 – 2:25 pm | Networking & Exhibitions |
Session III Immunotherapy Moderator: Dr. Michelle Chen |
|
2:25 – 2:55 pm | The new era in immuno-oncology: anti-PD-1 and beyond Dr. Juha Punnonen, Executive Director, Merck |
2:55 – 3:25 pm | New technologies in CAR-T therapy for treatment of solid tumors and reducing “Cytokine Storm” Dr. Cheng Liu, Founder & CEO, Eureka Therapeutics |
3:25 – 3:35 pm | Networking & Exhibitions |
Session IV: Panel Discussion Moderator: Dr. Lin Sun-Hoffman |
|
3:35 – 4:25 pm | Gene editing: Science and legal stories behind CRISPR Dr. Stanley Qi, Assistant Professor, Stanford University Dr. Ruhong Jiang, Co-founder and CEO, Applied StemCell, Inc. Dr. Lin Sun-Hoffman, J.D., President, Sun-Hoffman Consulting |
4:25 – 4:30 pm | Closing Remarks Dr. Mark Chen, 2016 CBA Conference Chair |
There will be a networking reception after the conference close in the Ultra Lounge at Crowne Plaza |